Thug an FDA ceadú brostaithe mobocertinib d’ailse scamhóg cealla neamh-bheag metastatach le sócháin isteach 20 EGFR exon XNUMX

September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertio..

KRAS G12C, KRAS RGQ trealamh PCR, GTPase RAS, sotorasib

Faigheann Sotorasib cead luathaithe ón FDA le haghaidh KRAS G12C mutant NSCLC

Lúnasa 2021: Dheonaigh an FDA faomhadh luathaithe do sotorasib (LumakrasTM, Amgen, Inc.), coscaire teaghlaigh RAS GTPase, d’othair aosach a bhfuil KRAS G12C mutated go háitiúil nó ailse scamhóg meiteastatach neamh-bheag cille (NSCLC) w.

ALK, B7461006, crizotinib, Lorbrena, lorlatinib, NCT03052608, Pfizer, Ventana ALK, Córais Leighis Ventana

Tá Lorlatinib ceadaithe ag an FDA le haghaidh cóireáil NSCLC metastatach ALK-dearfach.

Lúnasa 2021: Fuair ​​Lorlatinib (Lorbrena, Pfizer Inc.) ceadú rialta FDA d’othair a bhfuil ailse scamhóg mheiteastatach neamh-bheag cille orthu (NSCLC) a bhfuil a gcuid tumaí lymphoma kinase anaplaisteach (ALK) -positive, mar a chinneann FDA-app.

lymphoma kinase anaplaisteach, B7461006, CDx Measúnacht, Bia agus Drugaí Riarachán, Lorbrena, lorlatinib, NCT03052608, NSCLC, Pfizer, Ventana ALK, Córais Leighis Ventana

Tá Lorlatinib ceadaithe ag an FDA le haghaidh cóireáil NSCLC metastatach ALK-dearfach

Lúnasa 2021: Fuair ​​Lorlatinib (Lorbrena, Pfizer Inc.) ceadú rialta FDA d’othair a bhfuil ailse scamhóg mheiteastatach neamh-bheag cille orthu (NSCLC) a bhfuil a gcuid tumaí lymphoma kinase anaplaisteach (ALK) -positive, mar a chinneann FDA-app.

cemiplimab-rwlc, EGFR, FDA, Bia agus Drugaí Riarachán, NCT03088540, NSCLC, Slonn PD-L1

Tá Cemiplimab-rwlc ceadaithe ag an FDA d’ailse scamhóg cille neamh-bheag le slonn ard PD-L1

Lúnasa 2021: Cheadaigh an FDA cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) le haghaidh cóireála céadlíne d’othair a bhfuil ailse scamhóg cille neamh-bheag chun cinn (NSCLC) (ardleibhéal áitiúil nach iarrthóirí ar mháinliacht iad.

FDA, KRAS G12C, Lumakras, NSCLC, sotorasib

Tá an chéad teiripe spriocdhírithe ceadaithe ag an FDA le haghaidh sóchán ailse scamhóg a measadh roimhe seo a bheith frithsheasmhach in aghaidh drugaí

20 Lúnasa, 2021: Le déanaí i mí na Bealtaine, d'fhormheas Riarachán Bia agus Drugaí na SA Lumakras (sotorasib) mar an chéad chóireáil d'othair aosacha a bhfuil ailse scamhóg neamh-bheag orthu agus a ndeachaigh faoi chóras amháin roimhe seo ar a laghad.

Toitíní

Níos mó ná 12% d’othair ailse scamhóg nua-dhiagnóisiú toitíní deataithe níos nuaí - tugann staidéar le fios

July 7th 2021 : Tobacco smoking is the leading cause of lung cancer, accounting for over 80% of all fatalities from the disease. People who do not smoke, however, are also susceptible to lung cancer. According to a new study, arou..

Friotaíocht drugaí in ailse scamhóg cille neamh-bheag

What to do about drug resistance of non-small cell lung cancer targeted drugs, you want to know hereLung cancer is the cancer with the highest morbidity and mortality in China. About 1.6 million people die of this disease each yea..

Cóireáil PD-1 agus PD-l1 ar ailse scamhóg

Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most..

Brigatinib le haghaidh ailse scamhóg cille neamh-bheag atá frithsheasmhach in aghaidh crizotinib ALK-dearfach

Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of the American Society of Oncolo..